Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$12.81
-2.6%
$12.72
$8.50
$23.00
$80.09MN/A37,647 shs166 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.44
+0.6%
$3.16
$2.57
$6.88
$21.44M0.639,025 shs3,426 shs
OncoCyte Corporation stock logo
OCX
OncoCyte
$3.18
+16.3%
$2.99
$1.92
$4.75
$91.52M0.9759,148 shs100,514 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.14
-4.2%
$1.15
$0.83
$5.39
$70.62M1.18742,626 shs485,185 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00%-2.59%-14.03%-15.11%+1,280,999,900.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-0.03%+4.85%-11.59%-44.53%
OncoCyte Corporation stock logo
OCX
OncoCyte
0.00%+17.59%+7.99%-6.62%+18.03%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
0.00%-6.56%-5.79%-5.79%-66.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.6713 of 5 stars
0.03.00.00.01.51.70.6
OncoCyte Corporation stock logo
OCX
OncoCyte
1.8897 of 5 stars
3.44.00.00.00.00.80.6
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.057 of 5 stars
3.42.00.00.02.50.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
OncoCyte Corporation stock logo
OCX
OncoCyte
2.75
Moderate Buy$6.0690.94% Upside
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.80
Moderate Buy$9.00689.47% Upside

Current Analyst Ratings Breakdown

Latest NAII, OCX, IZTC, and PYXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
OncoCyte Corporation stock logo
OCX
OncoCyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
5/21/2025
OncoCyte Corporation stock logo
OCX
OncoCyte
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $8.00
5/19/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/13/2025
OncoCyte Corporation stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
4/8/2025
OncoCyte Corporation stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
3/28/2025
OncoCyte Corporation stock logo
OCX
OncoCyte
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
3/25/2025
OncoCyte Corporation stock logo
OCX
OncoCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$4.00 ➝ $4.00
3/25/2025
OncoCyte Corporation stock logo
OCX
OncoCyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
OncoCyte Corporation stock logo
OCX
OncoCyte
$3.84M23.63N/AN/A($0.70) per share-4.54
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$16.15M4.37N/AN/A$2.03 per share0.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
OncoCyte Corporation stock logo
OCX
OncoCyte
-$60.66M-$3.53N/AN/AN/A-1,516.06%-215.59%-27.23%8/6/2025 (Estimated)
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$77.33M-$1.59N/AN/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)

Latest NAII, OCX, IZTC, and PYXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.29-$0.35-$0.06-$0.35N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
OncoCyte Corporation stock logo
OCX
OncoCyte
-$0.24-$0.26-$0.02-$0.26$0.13 million$2.14 million
3/24/2025Q4 2024
OncoCyte Corporation stock logo
OCX
OncoCyte
-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
OncoCyte Corporation stock logo
OCX
OncoCyte
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
OncoCyte Corporation stock logo
OCX
OncoCyte
0.20
3.74
3.70
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
7.75
7.75

Institutional Ownership

CompanyInstitutional Ownership
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
OncoCyte Corporation stock logo
OCX
OncoCyte
55.35%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
OncoCyte Corporation stock logo
OCX
OncoCyte
12028.60 million28.01 millionNo Data
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
6061.95 million55.38 millionOptionable

Recent News About These Companies

Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14

New MarketBeat Followers Over Time

Media Sentiment Over Time

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$12.81 -0.34 (-2.59%)
As of 06/13/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.44 +0.02 (+0.56%)
Closing price 06/18/2025 03:58 PM Eastern
Extended Trading
$3.47 +0.03 (+0.87%)
As of 06/18/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

OncoCyte stock logo

OncoCyte NASDAQ:OCX

$3.18 +0.45 (+16.30%)
Closing price 06/17/2025 07:21 PM Eastern
Extended Trading
$3.18 0.00 (0.00%)
As of 06/17/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$1.14 -0.05 (-4.20%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$1.14 +0.01 (+0.44%)
As of 06/18/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.